WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at the Stifel 2023 Healthcare Conference on Wednesday, November 15th at 11:30 am ET. Disc will also give presentations at the Jefferies London Healthcare Conference on Thursday, November 16th at 9:30 am GMT / 4:30 am ET and the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30th at 2:30 pm ET.
A live webcast of the presentations will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
About Disc
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Verge Scientific Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Christina Tartaglia
Stern Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$76.98 |
Daily Change: | 5.02 6.98 |
Daily Volume: | 420,429 |
Market Cap: | US$2.680B |
September 30, 2025 August 07, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load